Xenetic Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James F. Parslow
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 945 Concord Street Framingham MA United States of America 01701
- IPO Date
- Jun 30, 2016
- CIK
- 0001534525
- Website
- xeneticbio.com
- Similar Companies
- Business
- Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company focused on advancing innovative immune-oncology technologies to address hard-to-treat cancers, including pancreatic ductal adenocarcinoma, colorectal carcinoma, and other solid tumors. The company develops its proprietary DNase platform, which targets neutrophil extracellular traps (NETs) implicated in cancer progression, metastasis, and resistance to therapies such as chemotherapy, checkpoint inhibitors, immunotherapies, and CAR-T; its pipeline features XBIO-015 as a systemic DNase program for pancreatic carcinoma and locally advanced or metastatic solid tumors, and XBIO-020 for solid tumors, with ongoing preclinical proof-of-concept studies combining DNase I with chemotherapy, immunotherapy, and CAR-T across cancer models. It also maintains the PolyXen drug delivery platform, licensed exclusively to Takeda Pharmaceutical Co. Ltd. for blood coagulation disorders generating royalty revenue, alongside exploratory personalized CAR-T technology (XCART) targeting B-cell lymphomas. Founded in 1996 and headquartered in Framingham, Massachusetts, Xenetic operates primarily in the United States with global partnerships. Recent developments include a December 2024 Clinical Trial Services Agreement with PeriNess Ltd. to manage regulatory approvals and investigator-initiated studies of DNase I combined with chemotherapy/immunotherapy for pancreatic cancer and solid tumors in Israel, and a July 2025 Clinical Study Agreement via PeriNess for DNase I with anti-CD19 CAR-T in large B-cell lymphoma at Tel-Aviv Sourasky Medical Center; the company expanded its R&D collaboration with The Scripps Research Institute and Dr. Alexey Stepanov in July 2025 to include lymphoma/leukemia models, extending it by four months effective November 2025, completed preclinical studies advancing toward a Phase 1 trial, and raised approximately $3.9 million in net proceeds from a public offering in October 2025.
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
Klotho Neurosciences (NASDAQ:KLTO) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Contrast
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
Ainos (NASDAQ:AIMD) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Analysis
Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Increase in Short Interest
Critical Contrast: Cumberland Pharmaceuticals (NASDAQ:CPIX) vs. Xenetic Biosciences (NASDAQ:XBIO)
Critical Review: Xenetic Biosciences (NASDAQ:XBIO) & Crinetics Pharmaceuticals (NASDAQ:CRNX)
Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Drop in Short Interest
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer